Evidence map›Paper›PMID 39143110›Full record

ArticleNature communications2024

Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM.

Fumiaki Ito, Ziyuan Li, Leonid Minakhin, Gurushankar Chandramouly, Mrityunjay Tyagi, Robert Betsch, John J Krais, Bernadette Taberi, Umeshkumar Vekariya, Marissa Calbert and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fumiaki Ito *Molecular and Computational Biology, Department of Biological Sciences and Chemistry, University of Southern California, Los Angeles, California, CA, 90089, USA.ORCID 0000-0002-2274-118X
Ziyuan Li *Molecular and Computational Biology, Department of Biological Sciences and Chemistry, University of Southern California, Los Angeles, California, CA, 90089, USA.
Leonid MinakhinDepartment of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Gurushankar ChandramoulyDepartment of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Mrityunjay TyagiDepartment of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Robert BetschNuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
John J KraisNuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.ORCID 0000-0002-3916-3435
Bernadette TaberiDepartment of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Umeshkumar VekariyaFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Marissa CalbertDepartment of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.ORCID 0000-0003-3005-8679
Tomasz SkorskiFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Neil JohnsonNuclear Dynamics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.ORCID 0000-0002-0276-0009
Xiaojiang S ChenMolecular and Computational Biology, Department of Biological Sciences and Chemistry, University of Southern California, Los Angeles, California, CA, 90089, USA. xiaojiac@usc.edu.ORCID 0000-0001-9574-0551
Richard T PomerantzDepartment of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. richard.pomerantz@jefferson.edu.ORCID 0000-0003-1194-9871

Funding

Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant CancersR01CA214799 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Neil Johnson · 2017 to 2026
$4.3M
Assessing DNA Polymerase Theta as a Therapeutic Target in BRCA1 Mutant CancerR01CA262466 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Neil Johnson · 2022 to 2026
$2.3M
Novel Mechanisms and Regulation of Mammalian Double-Strand Break RepairR35GM152198 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI Richard T Pomerantz · 2024 to 2026
$2.1M
Structure and Function of DNA Polymerase ThetaR01GM130889 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI POMERANTZ, RICHARD T · 2019 to 2022
$1.6M
NCI NIH HHS R01 CA214799NCI NIH HHS R01 CA262466NIGMS NIH HHS R01 GM130889NIGMS NIH HHS R35 GM152198U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R01GM130889
6 · The paper itself

Abstract

DNA polymerase theta (Polθ) is a DNA helicase-polymerase protein that facilitates DNA repair and is synthetic lethal with homology-directed repair (HDR) factors. Thus, Polθ is a promising precision oncology drug-target in HDR-deficient cancers. Here, we characterize the binding and mechanism of action of a Polθ helicase (Polθ-hel) small-molecule inhibitor (AB25583) using cryo-EM. AB25583 exhibits 6 nM IC

Indexed as

Cryoelectron MicroscopyDNA-Directed DNA PolymeraseDNA HelicasesDNA Polymerase thetaAdenosine TriphosphatasesBRCA1 ProteinBRCA2 ProteinCell Line, TumorEnzyme InhibitorsHumansModels, MolecularPhthalazinesPiperazinesProtein BindingAdenosine TriphosphatasesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanDNA-Directed DNA PolymeraseDNA HelicasesDNA Polymerase thetaEnzyme InhibitorsolaparibPhthalazinesPiperazines

Identifiers

PMID39143110
PMCPMC11324745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.